𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Target molecules in specific immunotherapy against prostate cancer

✍ Scribed by Mamoru Harada; Masanori Noguchi; Kyogo Itoh

Publisher
Springer
Year
2003
Tongue
English
Weight
180 KB
Volume
8
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Specific immunotherapy against occult ca
Specific immunotherapy against occult cancer metastases
✍ Weixin Lu; Zhongyun Dong; Cherrie Donawho; Isaiah J. Fidler πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 892 KB

## Abstract We investigated the efficacy of a preparation containing High Five (H5) insect cells infected with recombinant baculovirus encoding the murine interferon‐β gene (H5BVIFN‐β) against established primary tumors and occult lung metastases. Injection of live or lyophilized H5BVIFN‐β into est

Progress in active specific immunotherap
Progress in active specific immunotherapy of prostate cancer
✍ Benjamin A. Tjoa; Gerald P. Murphy πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system

Tumor target prostate specific membrane
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
✍ Arundhati Ghosh; Warren D.W. Heston πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 177 KB

## Abstract Prostate specific membrane antigen (PSMA), is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer as well as neovasculature of most of the solid tumors, but not in the vasculature of the normal tissues. This unique expression of PSMA makes it an impo

Prostate-specific antigen: A surrogate e
Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
✍ SchrοΏ½der, Fritz H.; Kranse, Ries; Barbet, Nik; Hop, Wim C.J.; Kandra, Albert; La πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 2 views

BACKGROUND. An endpoint for clinical trials of prostate cancer which simplifies traditional endpoints (response of measurable lesions, progression rates, and death) is urgently needed. This is especially true for hormone-unresponsive disease, for which many new drugs are presently in a development p